-
Potential Freidreich’s Ataxia Gene Therapy Focus of Neurocrine, Voyager Partnership
Neurocrine Biosciences and Voyager Therapeutics are collaborating on developing gene therapies, including VY-FXN01 for Friedreich’s ataxia. Click here to read more about this potential therapy.
Are you interested in more stories about gene therapies for FA?
Sorry, there were no replies found.
Log in to reply.